Scientific Evidence

Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma

Mar 2015

Initial development and validation of the 23-GEP establishing a high level of sensitivity and specificity in a broad range of histopathological subtypes.

Author: Clarke L, et al.

Publication: Journal of Cutaneous Pathology

Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy

Mar 2015

Assessment of the prognostic accuracy of GEP and sentinel lymph node biopsy (SLNB) tests, independently and in combination, in a multicenter cohort of 217 patients.

Author: Gerami P, et al.

Publication: Journal of the American Academy of Dermatology

Analytical validation of a melanoma diagnostic gene signature using formalin-fixed paraffin-embedded melanocytic lesions

Mar 2015

Analytical validation study to establish precision, dynamic range, RNA yield, reproducibility, and melanin inhibition.

Author: Warf MB, et al.

Publication: Biomarkers in Medicine

The economic burden of adults with major depressive disorder in the United States (2005 and 2010)

Feb 2015

Author: Greenberg, et al.

Publication: J Clin Psychiatry

Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma

Jan 2015

Multicenter study shows clear and significant separation of risk between Class 1 and Class 2 result for DFS, DMFS, MSS, OS using Kaplan-Maier analysis.

Author: Gerami P, et al.

Publication: Clinical Cancer Research

GNAQ and GNA11 mutations in uveal melanoma

Dec 2014

This review will discuss the multiple activated signaling targets downstream of mutant GNAQ and GNA11 in uveal melanoma, including MEK, PI3-kinase/Akt, protein kinase C, and YAP. This knowledge has led to the rapid expansion of clinical trials that are specific to patients with uveal melanoma and promises future breakthroughs in therapies.

Author: Shoushtari AN, et al.

Publication: Melanoma Res

Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses

Dec 2014

Assess current clinical practices for uveal melanoma (UM) and the impact of molecular prognostic testing on treatment decisions.

Author: Aaberg TM, et al.

Publication: Clin Ophthalmol

Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in Uveal Melanoma

Aug 2014

Somatic mutations in GNAQGNA11SF3B1EIF1AX, and BAP1 have been identified in uveal melanoma (UM). The aim of this study was to determine whether mutations in these genes in primary tumors were associated with metastases in individuals diagnosed with UM.

Author: Ewens KG, et al.

Publication: Investigative Ophthalmology & Visual Science

Recent developments in prognostic and predictive testing in uveal melanoma

May 2014

Purpose of review: To provide an update on the rapidly evolving methods for assessing prognosis and predicting response to targeted molecular therapy in uveal melanoma.

Author: Field MG, et al.

Publication: Curr Opin Ophthalmol

Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women's Hospital tumor staging for cutaneous squamous cell carcinoma

Dec 2013

To compare American Joint Committee on Cancer (AJCC), International Union Against Cancer (UICC), and Brigham and Women's Hospital (BWH) tumor (T) staging systems for cutaneous squamous cell carcinoma and validate BWH staging against prior data.

Author: Karia PS, et al.

Publication: Journal of Clinical Oncology

Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications

Nov 2013

To determine the relative sufficiency of paired aspirates of posterior uveal melanomas obtained by FNAB for cytopathology and GEP, and their prognostic significance for predicting death from metastasis.

Author: Correa ZM, et al.

Publication: Graefes Arch Clin Exp Ophthalmol

SF3B1 mutations are associated with alternative splicing in uveal melanoma

Oct 2013

Our data show that despite its dismal prognosis, uveal melanoma is a relatively simple genetic disease characterized by recurrent chromosomal losses and gains and a low mutational burden. We show that SF3B1 is recurrently mutated in uveal melanoma, and the mutations are associated with aberrant alternative splicing.

Author: Furney SJ, et al.

Publication: Cancer Discovery